Envista (NVST) 10-Q 2 Aug 23 2023 Q2 Quarterly report Financial data

Cover Page

Cover Page - shares	6 Months Ended
	Jun. 30, 2023	Jul. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2023
Document Transition Report	false
Entity File Number	001-39054
Entity Registrant Name	ENVISTA HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	83-2206728
Entity Address, Address Line One	200 S. Kraemer Blvd., Building E
Entity Address, City or Town	Brea,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92821-6208
City Area Code	714
Local Phone Number	817-7000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	NVST
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		163,823,852
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q2
Entity Central Index Key	0001757073

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 651.7	$ 606.9
Trade accounts receivable, less allowance for credit losses of $16.3 and $16.2, respectively	415.2	393.5
Inventories, net	297	300.8
Prepaid expenses and other current assets	125	123.4
Total current assets	1,488.9	1,424.6
Property, plant and equipment, net	300.1	293.6
Operating lease right-of-use assets	129.6	131.8
Other long-term assets	151.7	153.7
Goodwill	3,493.8	3,496.6
Other intangible assets, net	1,043.1	1,086.7
Total assets	6,607.2	6,587
Current liabilities:
Short-term debt	511.5	510
Trade accounts payable	176.8	228.3
Accrued expenses and other liabilities	434	471.4
Operating lease liabilities	28.5	27
Total current liabilities	1,150.8	1,236.7
Operating lease liabilities	116.8	121.4
Other long-term liabilities	153	151.3
Long-term debt	875.6	870.7
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value, 15.0 million shares authorized; no shares issued or outstanding at June 30, 2023 and December 31, 2022	0	0
Common stock - $0.01 par value, 500.0 million shares authorized; 164.5 million shares issued and 163.8 million shares outstanding at June 30, 2023; 163.7 million shares issued and 163.2 million shares outstanding at December 31, 2022	1.6	1.6
Additional paid-in capital	3,719.2	3,699
Retained earnings	827.1	731.4
Accumulated other comprehensive loss	(236.9)	(225.1)
Total stockholders’ equity	4,311	4,206.9
Total liabilities and stockholders’ equity	$ 6,607.2	$ 6,587

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 16.3	$ 16.2
Preferred stock, par value (in USD per share)	$ 0.01	$ 0.01
Preferred shares authorized (in shares)	15,000,000	15,000,000
Preferred shares issued (in shares)	0	0
Preferred shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	500,000,000	500,000,000
Common stock, shares issued (in shares)	164,500,000	163,700,000
Common stock, shares outstanding (in shares)	163,800,000	163,200,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Income Statement [Abstract]
Sales	$ 662.4	$ 645.8	$ 1,289.6	$ 1,277.2
Cost of sales	283.8	276	548.3	533.3
Gross profit	378.6	369.8	741.3	743.9
Operating expenses:
Selling, general and administrative	272.9	279.5	539	537.7
Research and development	26.8	25.1	51.3	49.5
Operating profit	78.9	65.2	151	156.7
Nonoperating income (expense):
Other income	7.1	0.3	7.4	0.6
Interest expense, net	(17.4)	(6.4)	(34.1)	(12.3)
Income before income taxes	68.6	59.1	124.3	145
Income tax expense	16.7	14.6	28.6	30.1
Income from continuing operations, net of tax	51.9	44.5	95.7	114.9
Income from discontinued operations, net of tax (Note 3)	0	2.6	0	7.1
Net income	$ 51.9	$ 47.1	$ 95.7	$ 122
Earnings per share:
Earnings from continuing operations - basic (in USD per share)	$ 0.32	$ 0.27	$ 0.58	$ 0.71
Earnings from continuing operations - diluted (in USD per share)	0.29	0.25	0.54	0.64
Earnings (loss) from discontinued operations - basic (in USD per share)	0	0.02	0	0.04
Earnings (loss) from discontinued operations - diluted (in USD per share)	0	0.01	0	0.04
Earnings - basic (in USD per share)	0.32	0.29	0.58	0.75
Earnings - diluted (in USD per share)	$ 0.29	$ 0.26	$ 0.54	$ 0.68
Average common stock and common equivalent shares outstanding:
Basic (in shares)	164	162.9	163.8	162.6
Diluted (in shares)	176.3	178.5	176.9	179.2

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 51.9	$ 47.1	$ 95.7	$ 122
Other comprehensive income (loss), net of income taxes:
Foreign currency translation adjustments	(25.9)	(72.9)	(11.1)	(132.5)
Cash flow hedge adjustments	0	0.5	0	1.9
Pension plan adjustments	(0.4)	(0.1)	(0.7)	(0.2)
Total other comprehensive loss, net of income taxes	(26.3)	(72.5)	(11.8)	(130.8)
Comprehensive income (loss)	$ 25.6	$ (25.4)	$ 83.9	$ (8.8)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (unaudited) - USD ($) $ in Millions	Total	Total Equity	Total Equity Adjustment	Total Equity Adjusted balance	Common Stock	Common Stock Adjusted balance	Additional Paid-in Capital	Additional Paid-in Capital Adjustment	Additional Paid-in Capital Adjusted balance	Retained Earnings	Retained Earnings Adjustment	Retained Earnings Adjusted balance	Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss Adjusted balance	Noncontrolling Interests	Noncontrolling Interests Adjusted balance
Balance, beginning of period at Dec. 31, 2021		$ 4,057.6	$ (56.4)	$ 4,001.2	$ 1.6	$ 1.6	$ 3,732.6	$ (77.8)	$ 3,654.8	$ 466.9	$ 21.4	$ 488.3	$ (143.5)	$ (143.5)	$ 0.4	$ 0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		13.1					13.1
Net income		74.9								74.9
Other comprehensive loss		(58.3)											(58.3)
Change in noncontrolling interest															(0.4)
Balance, end of period at Apr. 01, 2022		4,030.9			1.6		3,667.9			563.2			(201.8)		0
Balance, beginning of period at Dec. 31, 2021		4,057.6	$ (56.4)	$ 4,001.2	1.6	$ 1.6	3,732.6	$ (77.8)	$ 3,654.8	466.9	$ 21.4	$ 488.3	(143.5)	$ (143.5)	0.4	$ 0.4
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 122
Other comprehensive loss	(130.8)												(130.8)
Balance, end of period at Jul. 01, 2022		4,016			1.6		3,678.4			610.3			(274.3)		0
Balance, beginning of period at Apr. 01, 2022		4,030.9			1.6		3,667.9			563.2			(201.8)		0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		10.5					10.5
Net income	47.1	47.1								47.1
Other comprehensive loss	(72.5)	(72.5)											(72.5)
Balance, end of period at Jul. 01, 2022		4,016			1.6		3,678.4			610.3			(274.3)		$ 0
Balance, beginning of period at Dec. 31, 2022	4,206.9	4,206.9			1.6		3,699			731.4			(225.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		13.8					13.8
Net income		43.8								43.8
Other comprehensive loss		14.5											14.5
Balance, end of period at Mar. 31, 2023		4,279			1.6		3,712.8			775.2			(210.6)
Balance, beginning of period at Dec. 31, 2022	4,206.9	4,206.9			1.6		3,699			731.4			(225.1)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	95.7
Other comprehensive loss	(11.8)												(11.8)
Balance, end of period at Jun. 30, 2023	4,311	4,311			1.6		3,719.2			827.1			(236.9)
Balance, beginning of period at Mar. 31, 2023		4,279			1.6		3,712.8			775.2			(210.6)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock-based award activity		6.4					6.4
Net income	51.9	51.9								51.9
Other comprehensive loss	(26.3)	(26.3)											(26.3)
Balance, end of period at Jun. 30, 2023	$ 4,311	$ 4,311			$ 1.6		$ 3,719.2			$ 827.1			$ (236.9)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022
Cash flows from operating activities:
Net income	$ 95.7	$ 122
Noncash items:
Depreciation	17.9	16.1
Amortization	52	50.3
Allowance for credit losses	3.2	3.6
Stock-based compensation expense	20.2	15.8
Gain on sale of equity investment	(6.9)	0
Gain on sale of property, plant and equipment	0	(1.1)
Gain on sale of KaVo treatment unit and instrument business	0	(8.9)
Restructuring charges	0.8	3.8
Impairment charges	0.2	4.9
Amortization of right-of-use assets	13.1	11.2
Amortization of debt discount and issuance costs	2.1	2
Change in trade accounts receivable	(24)	(56.6)
Change in inventories	(3.9)	(29.5)
Change in trade accounts payable	(47.1)	5.9
Change in prepaid expenses and other assets	(1.1)	(17.4)
Change in accrued expenses and other liabilities	(27.2)	(80.9)
Change in operating lease liabilities	(16.8)	(15.5)
Net cash provided by operating activities	78.2	25.7
Cash flows from investing activities:
Payments for additions to property, plant and equipment	(31.6)	(31.9)
Proceeds from sale of equity investment	10.7	0
Acquisitions, net of cash acquired	0	(569.8)
Proceeds from sale of KaVo treatment unit and instrument business, net	0	28.8
All other investing activities, net	(3.9)	(13.6)
Net cash used in investing activities	(24.8)	(586.5)
Cash flows from financing activities:
Proceeds from stock option exercises	5.9	15.4
Tax withholding payment related to net settlement of equity awards	(6.4)	(8.1)
Proceeds from borrowings	0	0.3
Repayment of borrowings	0	(0.5)
All other financing activities	1.6	0
Net cash provided by financing activities	1.1	7.1
Effect of exchange rate changes on cash and cash equivalents	(9.7)	3.2
Net change in cash and cash equivalents	44.8	(550.5)
Beginning balance of cash and cash equivalents	606.9	1,073.6
Ending balance of cash and cash equivalents	651.7	523.1
Supplemental data:
Cash paid for interest	35.3	13.8
Cash paid for taxes	33.5	52.6
ROU assets obtained in exchange for operating lease obligations	$ 12.1	$ 18.3

Business And Basis Of Presentat

Business And Basis Of Presentation	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and Basis of Presentation	BUSINESS AND BASIS OF PRESENTATION Business Overview The Company provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, as well as to improve the aesthetics of the human smile. The Company is a worldwide provider of a broad range of dental implants, orthodontic appliances, general dental consumables, equipment and services and is dedicated to driving technological innovations that help dental professionals improve clinical outcomes and enhance productivity. The Company operates in two business segments: Specialty Products & Technologies and Equipment & Consumables. The Company’s Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Company’s Equipment & Consumables segment primarily develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; endodontic systems and related consumables; and restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products. Basis of Presentation All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included in the financial statements. All significant intercompany accounts and transactions between the businesses comprising the Company have been eliminated in the accompanying Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying Condensed Consolidated Financial Statements contain all adjustments (consisting of only normal recurring adjustments and reclassifications to conform to current year presentation) necessary to present fairly the financial position of the Company as of June 30, 2023 and December 31, 2022, and its results of operations for the three and six month periods ended June 30, 2023 and July 1, 2022 and cash flows for the six month periods ended June 30, 2023 and July 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and accompanying notes for the three years ended December 31, 2022, included in the Annual Report on Form 10-K filed by the Company with the SEC on February 16, 2023. As discussed in Note 3, Discontinued Operations, on December 31, 2021, the Company sold substantially all of its KaVo dental treatment unit and instrument business (the "KaVo Treatment Unit and Instrument Business"), which was part of the Company’s Equipment and Consumables segment. However, the transfer of assets in certain countries was not executed and closed until 2022 (“Deferred Local Closing”). As a result, the financial results related to the Deferred Local Closing countries were reported as discontinued operations and all segment information and descriptions exclude the activity related to those countries for the three and six months ended July 1, 2022. As of December 31, 2022, all Deferred Local Closings were completed and therefore there is no discontinued operations activity reported for the three and six months ended June 30, 2023. Risks and Uncertainties The Company is subject to risks and uncertainties as a result of the novel coronavirus (“COVID-19”) pandemic. The extent of the impact of the COVID-19 pandemic on the Company remains uncertain and difficult to predict because of the dynamic and evolving nature of the situation. The global impact of the outbreak continues to adversely affect many industries, and different geographies continue to reflect the effects of public health restrictions in various ways. The economic recovery following the impact of the COVID-19 pandemic is only partially underway and has been gradual, uneven and characterized by meaningful dispersion across sectors and regions with uncertainty regarding its ultimate length and trajectory. During the three and six months ended June 30, 2023, notwithstanding improvement in many markets in which the Company operates due to a return to more normalized business operations, certain markets continued to be adversely impacted by COVID-19. In addition, Russia’s invasion of Ukraine and the global response to this invasion, including sanctions imposed by the U.S. and other countries, could have an adverse impact on the Company’s overall business, including impacting the Company’s ability to market and sell products in the affected regions, potentially heightening the risk of cyber security attacks, impacting its ability to enforce its intellectual property rights in Russia, creating disruptions in the global supply chain, and by potentially having an adverse impact on the global economy, financial markets, energy markets, currency rates and otherwise. Accounting Standards Recently Adopted In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40),”

Acquisitions

Acquisitions	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	ACQUISITIONS The Company continually evaluates potential acquisitions that either strategically fit with the Company’s existing portfolio or expand the Company’s portfolio into new and attractive business areas. The Company has completed a number of acquisitions that have been accounted for as business combinations and have resulted in the recognition of goodwill in the Company’s Condensed Consolidated Financial Statements. Among other things, goodwill arises because the purchase prices for these businesses reflect a number of factors including the future earnings and cash flow potential of these businesses, the multiple to earnings, cash flow and other factors at which similar businesses have been purchased by other acquirers, the competitive nature of the processes by which the Company acquired the businesses, avoidance of the time and costs which would be required (and the associated risks that would be encountered) to enhance the Company’s existing product offerings to key target markets and enter into new and profitable businesses and the complementary strategic fit and resulting synergies these businesses bring to existing operations. The Company makes an initial allocation of the purchase price at the date of acquisition based upon its understanding of the fair value of the acquired assets and assumed liabilities. The Company obtains this information during due diligence and through other sources. For those assets and liabilities that were accounted for on a preliminary basis, the Company may up to 12 months after closing, refine the estimates of fair value and more accurately allocate the purchase price. Only items that existed as of the acquisition date are considered for subsequent adjustment. During the year ended December 31, 2022, the Company completed the following acquisitions which were accounted for under Accounting Standards Codification 805 Business Combination s using the acquisition method of accounting: Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. On July 5, 2022, the Company acquired all of the equity of Osteogenics Biomedical Inc., Allotech LLC and OBI Biologics, Inc. (together "Osteogenics") for total consideration of approximately $128.2 million, subject to certain customary adjustments as provided in the Equity Purchase Agreement dated May 17, 2022. Osteogenics develops innovative regenerative solutions for periodontists, oral and maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world, and is part of the Company’s Specialty Products & Technologies segment. Carestream Dental Technology Parent Limited’s Intraoral Scanner Business On April 20, 2022, the Company completed the acquisition of Carestream Dental Technology Parent Limited’s (“Carestream Dental”) intraoral scanner business (the “Intraoral Scanner Business”) for total consideration of $580.3 million, including contingent consideration of $7.5 million, and subject to certain customary adjustments as provided in the Stock and Asset Purchase Agreement dated December 21, 2021 and as subsequently amended by the closing agreement dated as of April 20, 2022 (together, the “IOS Purchase Agreement”). The Intraoral Scanner Business manufactures, markets, sells, commercializes, distributes, services, trains, supports, and maintains operations of intraoral scanners and software, and is part of the Company’s Equipment & Consumables segment. The Company purchased the Intraoral Scanner Business through the acquisition of certain assets and the assumption of certain liabilities as well as the acquisition of all of the equity of certain subsidiaries of Carestream Dental. The following table summarizes the fair values of the assets acquired and liabilities assumed as of the respective acquisition dates ($ in millions): Osteogenics Intraoral Scanner Business Assets acquired: Cash $ 2.1 $ 2.7 Accounts receivable 2.5 0.1 Inventories 13.3 6.1 Intangible assets 53.0 129.8 Property, plant and equipment — 0.3 Prepaids and Other Current Assets 1.3 — Goodwill 77.3 373.1 Non-current deferred tax asset — 96.0 Operating lease right-of-use assets 2.6 0.9 Other long-term assets 4.9 0.2 Total assets acquired 157.0 609.2 Liabilities assumed: Accounts payable (4.1) (0.5) Accrued expenses and other liabilities (2.5) (27.9) Non-current deferred tax liability (14.3) — Other long-term liabilities (5.8) — Operating lease liabilities (2.1) (0.5) Total liabilities assumed (28.8) (28.9) Total net assets acquired $ 128.2 $ 580.3 The intangible assets acquired consist of trade name, developed technology, and customer relationships. The weighted average amortization period of the acquired intangible assets in the aggregate is 8 and 10 years for the Intraoral Scanner Business and Osteogenics, respectively. The excess of the purchase price over the fair value assigned to the assets acquired and liabilities assumed represents the goodwill resulting from the acquisitions. Goodwill attributable to the acquisitions has been recorded as a non-current asset and is not amortized, but is subject to review at least on an annual basis for impairment. Goodwill recognized was primarily attributable to expected operating efficiencies and expansion opportunities in the businesses acquired. Goodwill is not deductible for income tax purposes. The pro forma impact of the acquisitions is not presented as the acquisitions were not considered material to the Company's Condensed Consolidated Financial Statements. For the three and six months ended July 1, 2022, legal, accounting, and other professional service costs associated with acquisitions were $8.2 million and $10.7 million, respectively, and have been recorded as selling, general and administrative expense in the Condensed Consolidated Statements of Operations. For the three and six months ended June 30, 2023, there were no legal, accounting, and other professional service costs associated with acquisitions.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	DISCONTINUED OPERATIONS On December 31, 2021, the Company sold substantially all of the KaVo Treatment Unit and Instrument Business (the “Divestiture”) to planmeca Verwaltungs Gmbh, Germany (“Planmeca”), pursuant to the master sale and purchase agreement (the “Purchase Agreement”) among the Company, Planmeca, and Planmeca Oy, as guarantor. However, the transfer of assets for Deferred Local Closing countries was not executed and closed until 2022. As of December 31, 2022, all Deferred Local Closings were completed and the Company received total net cash consideration of $386.4 million in accordance with the terms of the Purchase Agreement. For the six months ended July 1, 2022, the Company recognized an earnout payment of $30.0 million. As all Deferred Local Closings were completed as of December 31, 2022, there are no discontinued operations reported for the three and six months ended June 30, 2023. The operating results of the Divestiture for the three and six months ended July 1, 2022 are reflected in the Condensed Consolidated Statements of Operations within income from discontinued operations, net of tax as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 1, 2022 Sales $ 2.0 $ 8.9 Cost of sales 1.1 7.0 Gross profit 0.9 1.9 Operating expenses: Selling, general and administrative 1.0 2.1 Research and development — — Operating loss (0.1) (0.2) Income tax expense — — Loss from discontinued operations (0.1) (0.2) Gain on sale of discontinued operations, net of tax 2.7 7.3 Net income from discontinued operations $ 2.6 $ 7.1

Credit Losses

Credit Losses	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Credit Losses	CREDIT LOSSES The allowance for credit losses is a valuation account deducted from accounts receivable to present the net amount expected to be collected. Accounts receivable are charged off against the allowance when management believes the uncollectibility of an accounts receivable balance is confirmed. Management estimates the adequacy of the allowance by using relevant available information, from internal and external sources, relating to past events, current conditions and forecasts. Historical credit loss experience provides the basis for estimation of expected credit losses and is adjusted as necessary using the relevant information available. The allowance for credit losses is measured on a collective basis when similar risk characteristics exist. The Company has identified one portfolio segment based on the following risk characteristics: geographic regions, product lines, default rates and customer specific factors. The factors used by management in its credit loss analysis are inherently subject to uncertainty. If actual results are not consistent with management’s estimates and assumptions, the allowance for credit losses may be overstated or understated and a charge or credit to net income (loss) may be required. The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2022 $ 16.2 Foreign currency translation (0.2) Provision for credit losses 3.2 Write-offs charged against the allowance (1.8) Recoveries (1.1) Balance at June 30, 2023 $ 16.3

Inventories

Inventories	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Inventories	INVENTORIES The classes of inventory are summarized as follows ($ in millions): June 30, 2023 December 31, 2022 Finished goods $ 229.5 $ 229.2 Work in process 22.2 23.9 Raw materials 102.2 103.4 Reserve for inventory obsolescence (56.9) (55.7) Total $ 297.0 $ 300.8

Property, Plant And Equipment

Property, Plant And Equipment	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Property, Plant And Equipment	PROPERTY, PLANT AND EQUIPMENT The classes of property, plant and equipment are summarized as follows ($ in millions): June 30, 2023 December 31, 2022 Land and improvements $ 10.0 $ 10.0 Buildings and improvements 158.3 154.5 Machinery, equipment and other assets 394.7 370.2 Construction in progress 63.8 71.2 Gross property, plant and equipment 626.8 605.9 Less: accumulated depreciation (326.7) (312.3) Property, plant and equipment, net $ 300.1 $ 293.6

Goodwill

Goodwill	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	GOODWILL The following is a rollforward of the Company’s goodwill by segment ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2022 $ 2,047.8 $ 1,448.8 $ 3,496.6 Foreign currency translation (7.8) 5.0 (2.8) Balance at June 30, 2023 $ 2,040.0 $ 1,453.8 $ 3,493.8

Accrued Expenses And Other Liab

Accrued Expenses And Other Liabilities	6 Months Ended
	Jun. 30, 2023
Accrued expenses and other [Abstract]
Accrued Expenses and Other Liabilities	ACCRUED EXPENSES AND OTHER LIABILITIES Accrued expenses and other liabilities were as follows ($ in millions): June 30, 2023 December 31, 2022 Current Noncurrent Current Noncurrent Compensation and benefits $ 114.1 $ 21.1 $ 148.0 $ 17.5 Sales and product allowances 63.7 1.5 85.1 1.3 Contract liabilities 102.6 8.3 78.9 8.6 Taxes, income and other 37.8 65.8 42.1 68.6 Restructuring-related employee severance, benefits and other 11.1 — 18.9 — Pension benefits 5.6 16.6 5.6 17.5 Loss contingencies 10.3 26.7 8.1 27.6 Derivative financial instruments — 1.7 — — Other 88.8 11.3 84.7 10.2 Total $ 434.0 $ 153.0 $ 471.4 $ 151.3

Hedging Transactions And Deriva

Hedging Transactions And Derivative Financial Instruments	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Hedging Transactions and Derivative Financial Instruments	HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS The Company uses cross-currency swap derivative contracts to partially hedge its net investments in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The cross-currency swap derivative contracts are agreements to exchange fixed-rate payments in one currency for fixed-rate payments in another currency. On January 17, 2023, the Company entered into a two-year cross-currency swap derivative contract, with a notional value of $150.0 million, with respect to its $650.0 million senior term loan facility. This contract effectively converts a portion of the $650.0 million senior term loan facility to an obligation denominated in euros and partially offsets the impact of changes in currency rates on foreign currency denominated net investments. This instrument matures on January 17, 2025. The Company also has foreign currency denominated long-term debt in the amount of €208.0 million. This senior euro term loan facility represents a partial hedge of the Company’s net investment in foreign operations against adverse movements in exchange rates between the U.S. dollar and the euro. The senior euro term loan facility is designated and qualifies as a non-derivative hedging instrument. The senior euro term loan facility matures in September 2024. Refer to Note 13 for further discussion of the senior euro term loan facility. The change in the fair value of the cross-currency swap instrument and the foreign currency translation of the senior euro term loan facility are recorded in accumulated other comprehensive loss in equity, in the accompanying Condensed Consolidated Balance Sheets, partially offsetting the foreign currency translation adjustment of the Company’s related net investment that is also recorded in accumulated other comprehensive loss as reflected in Note 14. The Company has also used interest rate swap derivative contracts to reduce its variability of cash flows related to interest payments with respect to its senior term and senior euro term loan facilities. The interest rate swap contracts exchanged interest payments based on variable rates for interest payments based on fixed rates. The changes in the fair value of these instruments were recorded in accumulated other comprehensive loss in equity (see Note 14). The interest income or expense from the cross-currency and interest rate swaps were recorded in interest expense, net in the Company’s Condensed Consolidated Statements of Operations consistent with the classification of interest expense attributable to the underlying debt. The Company did not have any outstanding interest rate swap contracts as of June 30, 2023. The following table summarizes the notional values as of June 30, 2023 and July 1, 2022 and pretax impact of changes in the fair values of instruments designated as net investment and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended June 30, 2023 and July 1, 2022 ($ in millions): Three Months Ended Three Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (1.5) $ 216.6 $ 13.1 Foreign currency contracts 150.0 (1.7) 650.0 36.2 Interest rate contract — — 250.0 0.7 Total $ 377.0 $ (3.2) $ 1,116.6 $ 50.0 Six Months Ended Six Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (4.3) $ 216.6 $ 19.9 Foreign currency contracts 150.0 (1.7) 650.0 54.1 Interest rate contracts — — 250.0 2.5 Total $ 377.0 $ (6.0) $ 1,116.6 $ 76.5 The Company did not reclassify any deferred gains or losses related to net investment and cash flow hedges from accumulated other comprehensive loss to income during the three and six months ended June 30, 2023 and July 1, 2022. In addition, the Company did not have any ineffectiveness related to net investment and cash flow hedges and therefore did not reclassify any portion of the above net investment and cash flow hedges from accumulated other comprehensive loss into income during the three and six months ended June 30, 2023 and July 1, 2022. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in investing activities in the accompanying Condensed Consolidated Statements of Cash Flows. The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): June 30, 2023 December 31, 2022 Derivative liabilities: Other long-term liabilities $ 1.7 $ — Nonderivative hedging instruments: Long-term debt $ 227.0 $ 222.7 Amounts related to the Company’s derivatives expected to be reclassified from accumulated other comprehensive loss to net income during the next 12 months are not significant.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Accounting standards define fair value based on an exit price model, establish a framework for measuring fair value where the Company’s assets and liabilities are required to be carried at fair value and provide for certain disclosures related to the valuation methods used within a valuation hierarchy as established within the accounting standards. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, or other observable characteristics for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from, or corroborated by, observable market data through correlation; and Level 3 inputs are unobservable inputs based on the Company’s assumptions. A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement in its entirety. A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Significant Other Significant Total June 30, 2023 Liabilities: Cross-currency swap derivative contracts $ — $ 1.7 $ — $ 1.7 Deferred compensation plans $ — $ 19.4 $ — $ 19.4 Contingent consideration $ — $ — $ 6.0 $ 6.0 December 31, 2022: Liabilities: Deferred compensation plans $ — $ 15.8 $ — $ 15.8 Contingent consideration $ — $ — $ 6.0 $ 6.0 Derivative Instruments The cross-currency swap derivative contract was classified as Level 2 in the fair value hierarchy as it is measured using the income approach with the relevant, foreign currency current exchange rates and forward curves as inputs. Refer to Note 9 for additional information. Deferred Compensation Plans Certain management employees of the Company participate in nonqualified deferred compensation programs that permit such employees to defer a portion of their compensation, on a pretax basis. All amounts deferred under this plan are unfunded, unsecured obligations and are presented as a component of the Company’s compensation and benefits accrual included in accrued expenses in the accompanying Condensed Consolidated Balance Sheets (refer to Note 8). Participants may choose among alternative earnings rates for the amounts they defer, which are primarily based on investment options within the Company’s 401(k) program. Changes in the deferred compensation liability under these programs are recognized based on changes in the fair value of the participants’ accounts, which are based on the applicable earnings rates on investment options within the Company’s 401(k) program. Amounts voluntarily deferred by employees into the Company stock fund and amounts contributed to participant accounts by the Company are deemed invested in the Company’s common stock and future distributions of such contributions will be made solely in shares of Company common stock, and therefore are not reflected in the above amounts. Contingent Consideration Contingent consideration represents a cash hold back intended to be used for certain liabilities related to the Company’s acquisition of the Intraoral Scanner Business (as further discussed in Note 2). Contingent consideration was classified as Level 3 in the fair value hierarchy as the estimated fair value was measured using a probability weighted discounted cash flow model. Fair Value of Financial Instruments The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): June 30, 2023 December 31, 2022 Carrying Amount Fair Value Carrying Amount Fair Value Liabilities: Contingent consideration $ 6.0 $ 6.0 $ 6.0 $ 6.0 Cross-currency swap derivative contracts $ 1.7 $ 1.7 $ — $ — Convertible senior notes due 2025 $ 511.5 $ 868.4 $ 510.0 $ 873.0 Long-term debt $ 875.6 $ 875.6 $ 870.7 $ 870.7

Warranty

Warranty	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Warranty	WARRANTY The Company generally accrues estimated warranty costs at the time of sale. In general, manufactured products are warranted against defects in material and workmanship when properly used for their intended purpose, installed correctly and appropriately maintained. Warranty periods depend on the nature of the product and range from 90 days up to the life of the product. The amount of the accrued warranty liability is determined based on historical information such as past experience, product failure rates or number of units repaired, estimated cost of material and labor and in certain instances estimated property damage. The accrued warranty liability is reviewed on a quarterly basis and may be adjusted as additional information regarding expected warranty costs becomes known. The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2022 $ 9.2 Accruals for warranties issued during the year 6.7 Settlements made (6.5) Effect of foreign currency translation 0.1 Balance at June 30, 2023 $ 9.5

Litigation And Contingencies

Litigation And Contingencies	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Litigation And Contingencies	LITIGATION AND CONTINGENCIES The Company records accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. For litigation matters that the Company has determined are both probable and can be reasonably estimated, the Company has accrued $37.0 million and $35.7 million as of June 30, 2023 and December 31, 2022, respectively, which are included in accrued liabilities in the Condensed Consolidated Balance Sheets. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; or there are numerous parties involved. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's Condensed Consolidated Balance Sheets, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for one or more of these matters in any reporting period may have a material adverse effect on the Company’s results of operations and cash flows for that period.

Debt And Credit Facilities

Debt And Credit Facilities	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Debt And Credit Facilities	DEBT AND CREDIT FACILITIES The components of the Company’s debt were as follows, net of debt issuance costs ($ in millions): June 30, 2023 December 31, 2022 Senior term loan facility due 2024 (the “Term Loan”) $ 648.8 $ 648.3 Senior euro term loan facility due 2024 (the “Euro Term Loan”) 226.8 222.4 Convertible senior notes due 2025 511.5 510.0 Total debt 1,387.1 1,380.7 Less: current portion (511.5) (510.0) Long-term debt $ 875.6 $ 870.7 Credit Facilities The Company maintains a $650.0 million Term Loan and a €208.0 million Euro Term Loan. Additionally, the Company maintains a revolving credit facility (together with the Term Loan and the Euro Term Loan, the “Senior Credit Facilities”) with an aggregate available borrowing capacity of $750.0 million and a $20.0 million sublimit for the issuance of standby letters of credit that can be used for working capital and other general corporate purposes. The Company may request further increases to the revolving credit facility in an aggregate amount not to exceed $350.0 million. As of June 30, 2023 and December 31, 2022, there were no borrowings outstanding under the revolving credit facility. The Senior Credit Facilities mature on September 20, 2024. Under the Senior Credit Facilities, borrowings bear interest as follows: (1) Eurocurrency Rate Loans (as defined in the Amended Credit Agreement) bear interest at a variable rate equal to the London inter-bank offered (“LIBOR”) rate plus a margin of between 0.785% and 1.625%, depending on the Company’s Consolidated Leverage Ratio (as defined in the Amended Credit Agreement) as of the last day of the immediately preceding fiscal quarter; and (2) Base Rate Loans (as defined in the Amended Credit Agreement) bear interest at a variable rate equal to (a) the highest of (i) the Federal funds rate (as published by the Federal Reserve Bank of New York from time to time) plus 0.50%, (ii) Bank of America’s “prime rate” as publicly announced from time to time and (iii) the Eurocurrency Rate (as defined in the Amended Credit Agreement) plus 1.0%, plus (b) a margin of between 0.00% and 0.625%, depending on the Company’s Consolidated Leverage Ratio as of the last day of the immediately preceding fiscal quarter. In no event will Eurocurrency Rate Loans or Base Rate Loans bear interest at a rate lower than 0.0%. In the event of LIBOR cessation, the Secured Overnight Financing Rate will be used as a replacement rate. In addition, the Company is required to pay a per annum facility fee of between 0.09% and 0.225% depending on the Company’s Consolidated Leverage Ratio as of the last day of the immediately preceding fiscal quarter and based on the aggregate commitments under the revolving credit facility, whether drawn or not. The interest rates for borrowings under the Term Loan were 6.44% and 5.98% as of June 30, 2023 and December 31, 2022, respectively. The interest rates for borrowings under the Euro Term Loan were 4.49% and 3.28% as of June 30, 2023 and December 31, 2022, respectively. Interest is payable quarterly for both the Term and Euro Term Loans. The Company is required to maintain a Consolidated Leverage Ratio of 3.75 to 1.00 or less and includes a provision that the maximum Consolidated Leverage Ratio will be increased to 4.25 to 1.00 for the four consecutive full fiscal quarters immediately following the consummation of any acquisition by the Company or any subsidiary of the Company in which the purchase price exceeds $100.0 million. The Company is also required to maintain a Consolidated Interest Coverage Ratio (as defined in the Amended Credit Agreement) of at least 3.00 to 1.00. The Company is subject to customary representations, warranties, conditions precedent, events of default, indemnities and affirmative and negative covenants, including covenants that, among other things, limit or restrict the Company’s and/or the Company’s subsidiaries’ ability, subject to certain exceptions and qualifications, to incur liens or indebtedness, merge, consolidate or sell or otherwise transfer assets, make dividends or distributions, enter into transactions with the Company’s affiliates and use proceeds of the debt financing for other than permitted uses. Additionally, upon the occurrence and during the continuance of an event of default, the lenders may declare the outstanding advances and all other obligations immediately due and payable. The Company was in compliance with all of its debt covenants as of June 30, 2023. Convertible Senior Notes (the “Notes”) On May 21, 2020, the Company issued the Notes due on June 1, 2025, unless earlier repurchased, redeemed or converted. The aggregate principal amount, which includes the initial purchasers’ exercise in full of their option to purchase an additional $67.5 million principal amount of the Notes, was $517.5 million. The net proceeds from the issuance, after deducting purchasers’ discounts and estimated offering expenses, were $502.6 million. The Company used part of the net proceeds to pay for the capped call transactions (“Capped Calls”) as further described below. The Notes accrue interest at a rate of 2.375% per annum, payable semi-annually in arrears on June 1 and December 1 of each year. The Notes have an initial conversion rate of 47.5862 shares of the Company’s common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $21.01 per share of the Company’s common stock and is subject to adjustment upon the occurrence of specified events. The Notes are governed by an indenture dated as of May 21, 2020 (the “Indenture”) between the Company and Wilmington Trust, National Association, as trustee. The Indenture does not contain any financial covenants or any restrictions on the payment of dividends, the incurrence of senior debt or other indebtedness or the issuance or repurchase of the Company’s securities by the Company. The Notes are the Company’s senior, unsecured obligations and are (i) equal in right of payment with the Company’s existing and future senior, unsecured indebtedness; (ii) senior in right of payment to the Company’s existing and future indebtedness that is expressly subordinated to the Notes; (iii) effectively subordinated to the Company’s existing and future secured indebtedness, to the extent of the value of the collateral securing that indebtedness; and (iv) structurally subordinated to all existing and future indebtedness and other liabilities, including trade payables, and (to the extent the Company is not a holder thereof) preferred equity, if any, of the Company’s subsidiaries. Holders of the Notes may convert their Notes at any time on or after December 2, 2024 until the close of business on the second scheduled trading day preceding the maturity date. Holders of the Notes will also have the right to convert the Notes prior to December 2, 2024, but only upon the occurrence of specified events. In December 2021, the Company made the irrevocable election to settle all Notes conversions through combination settlement, satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in cash, shares of the Company’s common stock or a combination of both. If a fundamental change occurs prior to the maturity date, holders of the Notes may require the Company to repurchase all or a portion of their Notes for cash at a repurchase price equal to 100.0% of the principal amount plus any accrued and unpaid interest. In addition, if specific corporate events occur prior to the maturity date, the Company would increase the conversion rate for a holder who elects to convert its Notes in connection with such an event in certain circumstances. As of June 30, 2023 and December 31, 2022, the stock price exceeded 130% of the conversion price of $21.01 in 20 days of the final 30 trading days ended June 30, 2023 and December 31, 2022, which satisfied one of the conditions permitting early conversion by holders of the Notes, therefore, the Notes are classified as short-term debt. The Notes will be redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after June 1, 2023 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding the redemption date, but only if the last reported sale price per share of the Company’s common stock exceeds 130.0% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such notice. In addition, calling any Note for redemption will constitute a “Make-Whole Fundamental Change” (as defined in the Indenture) with respect to that Note, in which case the conversion rate applicable to the conversion of that Note will be increased in certain circumstances if it is converted after it is called for redemption. The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Contractual interest expense $ 3.0 $ 3.0 $ 6.1 $ 6.1 Amortization of debt issuance costs 0.8 0.8 1.5 1.5 Total interest expense $ 3.8 $ 3.8 $ 7.6 $ 7.6 For the three and six months ended June 30, 2023 and July 1, 2022, the debt issuance costs were amortized using an annual effective interest rate of 3.0% to interest expense over the term of the Notes. As of June 30, 2023 and December 31, 2022, the if-converted value of the Notes exceeded the outstanding principal amount by $315.8 million and $311.7 million, respectively. Debt Issuance Costs The remaining unamortized debt issuance costs for the Convertible Senior Notes, Term Loan and Euro Term Loan were as follows ($ in millions): June 30, 2023 December 31, 2022 Convertible Senior Notes $ 6.0 $ 7.5 Term Loan 1.2 1.7 Euro Term Loan 0.2 0.3 $ 7.4 $ 9.5 The above unamortized debt issuance costs have been netted against their respective aggregate principal amounts of the related debt and are being amortized to interest expense over the term of the respective debt. Capped Call Transactions In connection with the offering of the Notes, the Company entered into Capped Calls with certain counterparties. The Capped Calls each have an initial strike price of approximately $21.01 per share, subject to certain adjustments, which corresponds to the initial conversion price of the Notes. The Capped Calls have initial cap prices of $23.79 per share, subject to certain adjustments. The Capped Calls cover, subject to anti-dilution adjustments, 2.9 million shares of the Company's common stock. The Capped Calls are generally intended to reduce or offset the potential dilution from shares of common stock issued upon any conversion of the Notes with such reduction or offset, as the case may be, subject to a cap based on the cap price. As the Capped Call transactions are considered indexed to the Company's own stock and are considered equity classified, they are recorded in equity and are not accounted for as derivatives. The cost of $20.7 million incurred in connection with the Capped Calls was recorded as a reduction to additional paid-in capital.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Accumulated Other Comprehensive Loss	ACCUMULATED OTHER COMPREHENSIVE LOSS The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended June 30, 2023 Balance, March 31, 2023 $ (225.7) $ 15.1 $ (210.6) Other comprehensive loss before reclassifications: Decrease (26.7) — (26.7) Income tax impact 0.8 — 0.8 Other comprehensive loss before reclassifications, net of income taxes (25.9) — (25.9) Amounts reclassified from accumulated other comprehensive loss: Increase — (0.5) (0.5) Income tax impact — 0.1 0.1 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — (0.4) (0.4) Net current period other comprehensive loss, net of income taxes (25.9) (0.4) (26.3) Balance, June 30, 2023 $ (251.6) $ 14.7 $ (236.9) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 1, 2022 Balance, April 1, 2022 $ (199.2) $ (0.3) $ (2.3) $ (201.8) Other comprehensive (loss) income before reclassifications: (Decrease) increase (60.4) 0.7 — (59.7) Income tax impact (12.5) (0.2) — (12.7) Other comprehensive (loss) income before reclassifications, net of income taxes (72.9) 0.5 — (72.4) Amounts reclassified from accumulated other comprehensive loss: Increase — — — — Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.1) (0.1) Net current period other comprehensive (loss) income, net of income taxes (72.9) 0.5 (0.1) (72.5) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended June 30, 2023 Balance, December 31, 2022 $ (240.5) $ 15.4 $ (225.1) Other comprehensive loss before reclassifications: Decrease (12.6) — (12.6) Income tax impact 1.5 — 1.5 Other comprehensive loss before reclassifications, net of income taxes (11.1) — (11.1) Amounts reclassified from accumulated other comprehensive loss: Increase — (0.9) (0.9) Income tax impact — 0.2 0.2 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — (0.7) (0.7) Net current period other comprehensive loss, net of income taxes (11.1) (0.7) (11.8) Balance, June 30, 2023 $ (251.6) $ 14.7 $ (236.9) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 1, 2022 Balance, December 31, 2021 $ (139.6) $ (1.7) $ (2.2) $ (143.5) Other comprehensive (loss) income before reclassifications: (Decrease) increase (114.2) 2.5 — (111.7) Income tax impact (18.3) (0.6) — (18.9) Other comprehensive (loss) income before reclassifications, net of income taxes (132.5) 1.9 — (130.6) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — — — Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.2) (0.2) Net current period other comprehensive (loss) income, net of income taxes (132.5) 1.9 (0.2) (130.8) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3)

Revenue

Revenue	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Revenue	REVENUE The following table presents the Company’s revenues disaggregated by geographical region for the three and six months ended June 30, 2023 and July 1, 2022 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, experienced extended periods of accelerated growth in gross domestic product and infrastructure, to include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Three Months Ended June 30, 2023 Three Months Ended July 1, 2022 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 178.3 $ 162.1 $ 340.4 $ 179.5 $ 160.3 $ 339.8 Western Europe 114.6 30.3 144.9 100.5 29.4 129.9 Other developed markets 22.2 10.1 32.3 23.0 10.3 33.3 Emerging markets 101.9 42.9 144.8 104.7 38.1 142.8 Total $ 417.0 $ 245.4 $ 662.4 $ 407.7 $ 238.1 $ 645.8 Six Months Ended June 30, 2023 Six Months Ended July 1, 2022 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 363.6 $ 301.5 $ 665.1 $ 358.8 $ 316.6 $ 675.4 Western Europe 231.6 62.4 294.0 206.8 61.4 268.2 Other developed markets 46.2 18.7 64.9 47.4 20.6 68.0 Emerging markets 185.6 80.0 265.6 191.8 73.8 265.6 Total $ 827.0 $ 462.6 $ 1,289.6 $ 804.8 $ 472.4 $ 1,277.2 Remaining Performance Obligations Remaining performance obligations include noncancelable purchase orders, extended warranty and service agreements and do not include revenue from contracts with customers with an original term of one year or less. As of June 30, 2023, the aggregate amount of the transaction price allocated to remaining performance obligations was $73.1 million and the Company expects to recognize revenue on the majority of this amount over the next 12 months. Contract Liabilities The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities. These contract liabilities are classified as either current or long-term in the Condensed Consolidated Balance Sheets based on the timing of when the Company expects to recognize revenue. As of June 30, 2023 and December 31, 2022, the contract liabilities were $110.9 million and $87.5 million, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. Revenue recognized during the six months ended June 30, 2023 and July 1, 2022 that was included in the contract liability balance at December 31, 2022 and December 31, 2021 was $53.2 million and $36.1 million, respectively. Significant Customers Sales to the Company’s largest customer were 12% of sales for both of the three months ended June 30, 2023 and July 1, 2022, and 11% of sales for both of the six months ended June 30, 2023 and July 1, 2022. Seasonality Based on historical experience, the Company generally has more sales in the second half of the calendar year than in the first half of the calendar year, with the first quarter typically having the lowest sales of the year. Based on historical customer buying patterns, the Company generally has more sales in the fourth quarter than in any other quarter of the year, driven in particular by capital spending in the Equipment & Consumables segment. As a result of this seasonality in sales, profitability in the Equipment & Consumables segment also tends to be higher in the second half of the year. There are no assurances that these historical trends will continue in the future.

Restructuring Activities And Re

Restructuring Activities And Related Impairments	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring Activities And Related Impairments	RESTRUCTURING ACTIVITIES AND RELATED IMPAIRMENTS Restructuring Activities The Company’s restructuring activities are undertaken as necessary to implement management’s strategy, streamline operations, take advantage of available capacity and resources, and ultimately achieve net cost reductions. These activities generally relate to the realignment of existing manufacturing capacity and closure of facilities and other exit or disposal activities, as it relates to executing the Company’s strategy, pursuant to significant restructuring programs. The related liability which is included in accrued liabilities in the Condensed Consolidated Balance Sheets is summarized below ($ in millions): Employee Severance Facility Exit Total Balance, December 31, 2022 $ 18.2 $ 0.7 $ 18.9 Costs incurred 13.2 4.3 17.5 Paid (21.2) (4.1) (25.3) Balance, June 30, 2023 $ 10.2 $ 0.9 $ 11.1 Restructuring related charges by segment were as follows ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Specialty Products & Technologies $ 6.2 $ 4.2 $ 7.8 $ 8.2 Equipment & Consumables 6.4 9.3 9.0 8.4 Other 1.0 1.3 1.1 1.9 Total $ 13.6 $ 14.8 $ 17.9 $ 18.5 Restructuring related charges were reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Cost of sales $ 4.8 $ 6.9 $ 6.3 $ 6.6 Selling, general and administrative expenses 8.8 7.9 11.6 11.9 Total $ 13.6 $ 14.8 $ 17.9 $ 18.5

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The Company’s effective tax rates from continuing operations of 24.3% and 23.0% for the three and six months ended June 30, 2023, respectively, and 24.7% and 20.8% for the three and six months ended July 1, 2022, respectively, differ from the U.S. federal statutory rate of 21.0% primarily due to the Company’s geographical mix of earnings and discrete tax benefits. On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022, which, among other things, implemented a 15% minimum tax on book income of certain large corporations, a 1% excise tax on net stock repurchases, and several tax incentives to promote clean energy. Based on the Company’s current analysis of the provisions, this legislation did not have a material impact on its Condensed Consolidated Financial Statements as of or for the three and six months ended June 30, 2023.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE Earnings per share is calculated by dividing the applicable income by the weighted average number of shares of common stock outstanding for the applicable period. Diluted earnings per share is computed based on the weighted average number of common shares outstanding plus the effect of dilutive potential shares outstanding during the period using the treasury stock method. Dilutive potential common shares include employee equity options, non-vested shares and similar instruments granted by the Company and the assumed conversion impact of the Notes. The Company will settle any Notes conversions through a combination settlement by satisfying the principal amount outstanding with cash and any Notes conversion value in excess of the principal amount in cash or shares of the Company’s common stock or any combination thereof. As such, the Company uses the treasury stock method for the assumed conversion of the Notes to compute the weighted average shares of common stock outstanding for diluted earnings per share. As the Company will settle the principal amount of the Notes in cash upon conversion, the Notes only have an impact on the Company's diluted earnings per share when the average share price of the Company’s common stock exceeds the conversion price of $21.01 per share in any applicable period. See the computation of earnings per share below for the dilutive impact of the Notes for the three and six months ended June 30, 2023 and July 1, 2022. In connection with the offering of the Notes, the Company entered into Capped Calls (see further discussion in Note 13), which are intended to reduce or offset the potential dilution from shares of common stock issued upon conversion of the Notes. However, this impact is not included when calculating potentially dilutive shares since their effect is anti-dilutive. The Capped Calls will mitigate dilution from the conversion of the Notes up to the Company’s common stock price of $23.79. If the Notes are converted at a price higher than $23.79 per share, the Capped Calls will no longer mitigate dilution from the conversion of the Notes. The table below presents the computation of basic and diluted earnings per share ($ and shares in millions, except per share amounts): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Numerator: Income from continuing operations, net of tax $ 51.9 $ 44.5 $ 95.7 $ 114.9 Income from discontinued operations, net of tax $ — $ 2.6 $ — $ 7.1 Net income $ 51.9 $ 47.1 $ 95.7 $ 122.0 Denominator: Weighted-average common shares outstanding used in basic earnings per share 164.0 162.9 163.8 162.6 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units 2.4 3.3 2.6 3.8 Assumed conversion of the Notes 9.9 12.3 10.5 12.8 Weighted average common shares outstanding used in diluted earnings per share 176.3 178.5 176.9 179.2 Earnings per share: Earnings from continuing operations - basic $ 0.32 $ 0.27 $ 0.58 $ 0.71 Earnings from continuing operations - diluted $ 0.29 $ 0.25 $ 0.54 $ 0.64 Earnings from discontinued operations - basic $ — $ 0.02 $ — $ 0.04 Earnings from discontinued operations - diluted $ — $ 0.01 $ — $ 0.04 Earnings - basic $ 0.32 $ 0.29 $ 0.58 $ 0.75 Earnings - diluted $ 0.29 $ 0.26 $ 0.54 $ 0.68 The following table presents the number of outstanding securities not included in the computation of diluted income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Stock-based awards 2.1 1.9 2.0 1.3

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION The Company operates and reports its results in two separate business segments, the Specialty Products & Technologies and Equipment & Consumables segments. When determining the reportable segments, the Company aggregated operating segments based on their similar economic and operating characteristics. Operating profit represents total revenues less operating expenses, excluding nonoperating income (expense), interest expense and income taxes. Operating profit amounts in the Other segment consist of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance. The identifiable assets by segment are those used in each segment’s operations. Inter-segment amounts are not significant and are eliminated to arrive at consolidated totals. The Company’s Specialty Products & Technologies products primarily include implants, regenerative products, prosthetics, orthodontic brackets, aligners and lab products. The Company’s Equipment & Consumables products primarily include traditional consumables such as bonding agents and cements, impression materials, infection prevention products and restorative products, while the Company’s equipment products primarily include digital imaging systems, software and other visualization and magnification systems. On December 31, 2021, the Company sold substantially all of its KaVo Treatment Unit and Instrument Business, which was part of the Company’s Equipment & Consumables segment. As a result, the financial results of the KaVo Treatment Unit and Instrument Business for the three and six months ended July 1, 2022, were reported as discontinued operations and all segment information and descriptions exclude the KaVo Treatment Unit and Instrument Business. As of December 31, 2022, all activities related to the sale of the KaVo Treatment Unit and Instrument Business were completed and therefore there are no discontinued operations reported for the three and six months ended June 30, 2023. Refer to Note 3 for more information on the Company’s discontinued operations. Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Sales: Specialty Products & Technologies $ 417.0 $ 407.7 $ 827.0 $ 804.8 Equipment & Consumables 245.4 238.1 462.6 472.4 Total $ 662.4 $ 645.8 $ 1,289.6 $ 1,277.2 Operating profit and reconciliation to income before taxes from continuing operations: Specialty Products & Technologies $ 55.7 $ 74.0 $ 126.8 $ 144.3 Equipment & Consumables 48.4 30.2 80.9 75.7 Other (25.2) (39.0) (56.7) (63.3) Operating profit 78.9 65.2 151.0 156.7 Nonoperating income (expense): Other income 7.1 0.3 7.4 0.6 Interest expense, net (17.4) (6.4) (34.1) (12.3) Income before taxes from continuing operations $ 68.6 $ 59.1 $ 124.3 $ 145.0 Identifiable assets: June 30, 2023 December 31, 2022 Specialty Products & Technologies $ 3,438.2 $ 3,475.7 Equipment & Consumables 2,473.5 2,455.3 Other 695.5 656.0 Total $ 6,607.2 $ 6,587.0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 51.9	$ 47.1	$ 95.7	$ 122

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Business And Basis Or Presentat

Business And Basis Or Presentation (Policies)	6 Months Ended
	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Principles	Basis of Presentation All revenues and costs as well as assets and liabilities directly associated with the business activity of the Company are included in the financial statements. All significant intercompany accounts and transactions between the businesses comprising the Company have been eliminated in the accompanying Condensed Consolidated Financial Statements. The Condensed Consolidated Financial Statements included herein have been prepared by the Company without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to such rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The accompanying Condensed Consolidated Financial Statements contain all adjustments (consisting of only normal recurring adjustments and reclassifications to conform to current year presentation) necessary to present fairly the financial position of the Company as of June 30, 2023 and December 31, 2022, and its results of operations for the three and six month periods ended June 30, 2023 and July 1, 2022 and cash flows for the six month periods ended June 30, 2023 and July 1, 2022. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s Consolidated Financial Statements and accompanying notes for the three years ended December 31, 2022, included in the Annual Report on Form 10-K filed by the Company with the SEC on February 16, 2023. As discussed in Note 3, Discontinued Operations, on December 31, 2021, the Company sold substantially all of its KaVo dental treatment unit and instrument business (the "KaVo Treatment Unit and Instrument Business"), which was part of the Company’s Equipment and Consumables segment. However, the transfer of assets in certain countries was not executed and closed until 2022 (“Deferred Local Closing”). As a result, the financial results related to the Deferred Local Closing countries were reported as discontinued operations and all segment information and descriptions exclude the activity related to those countries for the three and six months ended July 1, 2022. As of December 31, 2022, all Deferred Local Closings were completed and therefore there is no discontinued operations activity reported for the three and six months ended June 30, 2023.
Accounting Standards Recently Adopted	Accounting Standards Recently Adopted In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40),”

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]
Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the respective acquisition dates ($ in millions): Osteogenics Intraoral Scanner Business Assets acquired: Cash $ 2.1 $ 2.7 Accounts receivable 2.5 0.1 Inventories 13.3 6.1 Intangible assets 53.0 129.8 Property, plant and equipment — 0.3 Prepaids and Other Current Assets 1.3 — Goodwill 77.3 373.1 Non-current deferred tax asset — 96.0 Operating lease right-of-use assets 2.6 0.9 Other long-term assets 4.9 0.2 Total assets acquired 157.0 609.2 Liabilities assumed: Accounts payable (4.1) (0.5) Accrued expenses and other liabilities (2.5) (27.9) Non-current deferred tax liability (14.3) — Other long-term liabilities (5.8) — Operating lease liabilities (2.1) (0.5) Total liabilities assumed (28.8) (28.9) Total net assets acquired $ 128.2 $ 580.3

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2023
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operations	The operating results of the Divestiture for the three and six months ended July 1, 2022 are reflected in the Condensed Consolidated Statements of Operations within income from discontinued operations, net of tax as follows ($ in millions): Three Months Ended Six Months Ended July 1, 2022 July 1, 2022 Sales $ 2.0 $ 8.9 Cost of sales 1.1 7.0 Gross profit 0.9 1.9 Operating expenses: Selling, general and administrative 1.0 2.1 Research and development — — Operating loss (0.1) (0.2) Income tax expense — — Loss from discontinued operations (0.1) (0.2) Gain on sale of discontinued operations, net of tax 2.7 7.3 Net income from discontinued operations $ 2.6 $ 7.1

Credit Losses (Tables)

Credit Losses (Tables)	6 Months Ended
	Jun. 30, 2023
Credit Loss [Abstract]
Allowance for Credit Loss	The rollforward of the allowance for credit losses is summarized as follows ($ in millions): Balance at December 31, 2022 $ 16.2 Foreign currency translation (0.2) Provision for credit losses 3.2 Write-offs charged against the allowance (1.8) Recoveries (1.1) Balance at June 30, 2023 $ 16.3

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2023
Inventory Disclosure [Abstract]
Schedule of Inventory	The classes of inventory are summarized as follows ($ in millions): June 30, 2023 December 31, 2022 Finished goods $ 229.5 $ 229.2 Work in process 22.2 23.9 Raw materials 102.2 103.4 Reserve for inventory obsolescence (56.9) (55.7) Total $ 297.0 $ 300.8

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	6 Months Ended
	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	The classes of property, plant and equipment are summarized as follows ($ in millions): June 30, 2023 December 31, 2022 Land and improvements $ 10.0 $ 10.0 Buildings and improvements 158.3 154.5 Machinery, equipment and other assets 394.7 370.2 Construction in progress 63.8 71.2 Gross property, plant and equipment 626.8 605.9 Less: accumulated depreciation (326.7) (312.3) Property, plant and equipment, net $ 300.1 $ 293.6

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Rollforward and Carrying Value Of Goodwill	The following is a rollforward of the Company’s goodwill by segment ($ in millions): Specialty Products & Technologies Equipment & Consumables Total Balance at December 31, 2022 $ 2,047.8 $ 1,448.8 $ 3,496.6 Foreign currency translation (7.8) 5.0 (2.8) Balance at June 30, 2023 $ 2,040.0 $ 1,453.8 $ 3,493.8

Accrued Expenses And Other Li_2

Accrued Expenses And Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2023
Accrued expenses and other [Abstract]
The components of accrued expenses and other liabilities	Accrued expenses and other liabilities were as follows ($ in millions): June 30, 2023 December 31, 2022 Current Noncurrent Current Noncurrent Compensation and benefits $ 114.1 $ 21.1 $ 148.0 $ 17.5 Sales and product allowances 63.7 1.5 85.1 1.3 Contract liabilities 102.6 8.3 78.9 8.6 Taxes, income and other 37.8 65.8 42.1 68.6 Restructuring-related employee severance, benefits and other 11.1 — 18.9 — Pension benefits 5.6 16.6 5.6 17.5 Loss contingencies 10.3 26.7 8.1 27.6 Derivative financial instruments — 1.7 — — Other 88.8 11.3 84.7 10.2 Total $ 434.0 $ 153.0 $ 471.4 $ 151.3

Hedging Transactions And Deri_2

Hedging Transactions And Derivative Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative instruments, gain (loss)	The following table summarizes the notional values as of June 30, 2023 and July 1, 2022 and pretax impact of changes in the fair values of instruments designated as net investment and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended June 30, 2023 and July 1, 2022 ($ in millions): Three Months Ended Three Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (1.5) $ 216.6 $ 13.1 Foreign currency contracts 150.0 (1.7) 650.0 36.2 Interest rate contract — — 250.0 0.7 Total $ 377.0 $ (3.2) $ 1,116.6 $ 50.0 Six Months Ended Six Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (4.3) $ 216.6 $ 19.9 Foreign currency contracts 150.0 (1.7) 650.0 54.1 Interest rate contracts — — 250.0 2.5 Total $ 377.0 $ (6.0) $ 1,116.6 $ 76.5
Schedule of notional amounts of outstanding derivative positions	The following table summarizes the notional values as of June 30, 2023 and July 1, 2022 and pretax impact of changes in the fair values of instruments designated as net investment and cash flow hedges in accumulated other comprehensive loss (“OCI”) for the three and six months ended June 30, 2023 and July 1, 2022 ($ in millions): Three Months Ended Three Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (1.5) $ 216.6 $ 13.1 Foreign currency contracts 150.0 (1.7) 650.0 36.2 Interest rate contract — — 250.0 0.7 Total $ 377.0 $ (3.2) $ 1,116.6 $ 50.0 Six Months Ended Six Months Ended Notional Amount Loss Recognized in OCI Notional Amount Gain Recognized in OCI Foreign currency denominated debt $ 227.0 $ (4.3) $ 216.6 $ 19.9 Foreign currency contracts 150.0 (1.7) 650.0 54.1 Interest rate contracts — — 250.0 2.5 Total $ 377.0 $ (6.0) $ 1,116.6 $ 76.5
Schedule of derivative instruments in statement of financial position, fair value	The Company’s derivative instruments, as well as its non-derivative debt instruments designated and qualifying as net investment hedges, were classified in the Company’s Condensed Consolidated Balance Sheets as follows ($ in millions): June 30, 2023 December 31, 2022 Derivative liabilities: Other long-term liabilities $ 1.7 $ — Nonderivative hedging instruments: Long-term debt $ 227.0 $ 222.7

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of financial assets and liabilities at carrying and fair value	A summary of financial assets and liabilities that are measured at fair value on a recurring basis were as follows ($ in millions): Quoted Prices in Significant Other Significant Total June 30, 2023 Liabilities: Cross-currency swap derivative contracts $ — $ 1.7 $ — $ 1.7 Deferred compensation plans $ — $ 19.4 $ — $ 19.4 Contingent consideration $ — $ — $ 6.0 $ 6.0 December 31, 2022: Liabilities: Deferred compensation plans $ — $ 15.8 $ — $ 15.8 Contingent consideration $ — $ — $ 6.0 $ 6.0 The carrying amounts and fair values of the Company’s financial instruments were as follows ($ in millions): June 30, 2023 December 31, 2022 Carrying Amount Fair Value Carrying Amount Fair Value Liabilities: Contingent consideration $ 6.0 $ 6.0 $ 6.0 $ 6.0 Cross-currency swap derivative contracts $ 1.7 $ 1.7 $ — $ — Convertible senior notes due 2025 $ 511.5 $ 868.4 $ 510.0 $ 873.0 Long-term debt $ 875.6 $ 875.6 $ 870.7 $ 870.7

Warranty (Tables)

Warranty (Tables)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Warranty accrual	The following is a rollforward of the Company’s accrued warranty liability ($ in millions): Balance at December 31, 2022 $ 9.2 Accruals for warranties issued during the year 6.7 Settlements made (6.5) Effect of foreign currency translation 0.1 Balance at June 30, 2023 $ 9.5

Debt And Credit Facilities (Tab

Debt And Credit Facilities (Tables)	6 Months Ended
	Jun. 30, 2023
Debt Disclosure [Abstract]
Components of debt	The components of the Company’s debt were as follows, net of debt issuance costs ($ in millions): June 30, 2023 December 31, 2022 Senior term loan facility due 2024 (the “Term Loan”) $ 648.8 $ 648.3 Senior euro term loan facility due 2024 (the “Euro Term Loan”) 226.8 222.4 Convertible senior notes due 2025 511.5 510.0 Total debt 1,387.1 1,380.7 Less: current portion (511.5) (510.0) Long-term debt $ 875.6 $ 870.7
Components of note interest expense	The following table sets forth total interest expense recognized related to the Notes ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Contractual interest expense $ 3.0 $ 3.0 $ 6.1 $ 6.1 Amortization of debt issuance costs 0.8 0.8 1.5 1.5 Total interest expense $ 3.8 $ 3.8 $ 7.6 $ 7.6
Components of unamortized debt discount and issuance costs	The remaining unamortized debt issuance costs for the Convertible Senior Notes, Term Loan and Euro Term Loan were as follows ($ in millions): June 30, 2023 December 31, 2022 Convertible Senior Notes $ 6.0 $ 7.5 Term Loan 1.2 1.7 Euro Term Loan 0.2 0.3 $ 7.4 $ 9.5

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2023
Equity [Abstract]
Schedule of accumulated other comprehensive income (loss)	The changes in accumulated other comprehensive loss by component are summarized below ($ in millions). Foreign Currency Translation Adjustments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended June 30, 2023 Balance, March 31, 2023 $ (225.7) $ 15.1 $ (210.6) Other comprehensive loss before reclassifications: Decrease (26.7) — (26.7) Income tax impact 0.8 — 0.8 Other comprehensive loss before reclassifications, net of income taxes (25.9) — (25.9) Amounts reclassified from accumulated other comprehensive loss: Increase — (0.5) (0.5) Income tax impact — 0.1 0.1 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — (0.4) (0.4) Net current period other comprehensive loss, net of income taxes (25.9) (0.4) (26.3) Balance, June 30, 2023 $ (251.6) $ 14.7 $ (236.9) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Three Months Ended July 1, 2022 Balance, April 1, 2022 $ (199.2) $ (0.3) $ (2.3) $ (201.8) Other comprehensive (loss) income before reclassifications: (Decrease) increase (60.4) 0.7 — (59.7) Income tax impact (12.5) (0.2) — (12.7) Other comprehensive (loss) income before reclassifications, net of income taxes (72.9) 0.5 — (72.4) Amounts reclassified from accumulated other comprehensive loss: Increase — — — — Income tax impact — — (0.1) (0.1) Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.1) (0.1) Net current period other comprehensive (loss) income, net of income taxes (72.9) 0.5 (0.1) (72.5) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3) Foreign Currency Translation Adjustments Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended June 30, 2023 Balance, December 31, 2022 $ (240.5) $ 15.4 $ (225.1) Other comprehensive loss before reclassifications: Decrease (12.6) — (12.6) Income tax impact 1.5 — 1.5 Other comprehensive loss before reclassifications, net of income taxes (11.1) — (11.1) Amounts reclassified from accumulated other comprehensive loss: Increase — (0.9) (0.9) Income tax impact — 0.2 0.2 Amounts reclassified from accumulated other comprehensive loss, net of income taxes — (0.7) (0.7) Net current period other comprehensive loss, net of income taxes (11.1) (0.7) (11.8) Balance, June 30, 2023 $ (251.6) $ 14.7 $ (236.9) Foreign Currency Translation Adjustments Unrealized Loss on Cash Flow Hedges Unrealized Pension Costs Total Accumulated Other Comprehensive Loss Six Months Ended July 1, 2022 Balance, December 31, 2021 $ (139.6) $ (1.7) $ (2.2) $ (143.5) Other comprehensive (loss) income before reclassifications: (Decrease) increase (114.2) 2.5 — (111.7) Income tax impact (18.3) (0.6) — (18.9) Other comprehensive (loss) income before reclassifications, net of income taxes (132.5) 1.9 — (130.6) Amounts reclassified from accumulated other comprehensive loss: Increase — — (0.2) (0.2) Income tax impact — — — — Amounts reclassified from accumulated other comprehensive loss, net of income taxes — — (0.2) (0.2) Net current period other comprehensive (loss) income, net of income taxes (132.5) 1.9 (0.2) (130.8) Balance, July 1, 2022 $ (272.1) $ 0.2 $ (2.4) $ (274.3)

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue by geographical region and type	The following table presents the Company’s revenues disaggregated by geographical region for the three and six months ended June 30, 2023 and July 1, 2022 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenues. The Company has historically defined emerging markets as developing markets of the world, which prior to the COVID-19 pandemic, experienced extended periods of accelerated growth in gross domestic product and infrastructure, to include Eastern Europe, the Middle East, Africa, Latin America and Asia (with the exception of Japan and Australia). The Company defines developed markets as all markets of the world that are not emerging markets. Three Months Ended June 30, 2023 Three Months Ended July 1, 2022 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 178.3 $ 162.1 $ 340.4 $ 179.5 $ 160.3 $ 339.8 Western Europe 114.6 30.3 144.9 100.5 29.4 129.9 Other developed markets 22.2 10.1 32.3 23.0 10.3 33.3 Emerging markets 101.9 42.9 144.8 104.7 38.1 142.8 Total $ 417.0 $ 245.4 $ 662.4 $ 407.7 $ 238.1 $ 645.8 Six Months Ended June 30, 2023 Six Months Ended July 1, 2022 Specialty Products & Technologies Equipment & Consumables Total Specialty Products & Technologies Equipment & Consumables Total Geographical region: North America $ 363.6 $ 301.5 $ 665.1 $ 358.8 $ 316.6 $ 675.4 Western Europe 231.6 62.4 294.0 206.8 61.4 268.2 Other developed markets 46.2 18.7 64.9 47.4 20.6 68.0 Emerging markets 185.6 80.0 265.6 191.8 73.8 265.6 Total $ 827.0 $ 462.6 $ 1,289.6 $ 804.8 $ 472.4 $ 1,277.2

Restructuring Activities And _2

Restructuring Activities And Related Impairments (Tables)	6 Months Ended
	Jun. 30, 2023
Restructuring and Related Activities [Abstract]
Restructuring and related costs	The related liability which is included in accrued liabilities in the Condensed Consolidated Balance Sheets is summarized below ($ in millions): Employee Severance Facility Exit Total Balance, December 31, 2022 $ 18.2 $ 0.7 $ 18.9 Costs incurred 13.2 4.3 17.5 Paid (21.2) (4.1) (25.3) Balance, June 30, 2023 $ 10.2 $ 0.9 $ 11.1
Schedule of restructuring reserve by type of cost	Restructuring related charges by segment were as follows ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Specialty Products & Technologies $ 6.2 $ 4.2 $ 7.8 $ 8.2 Equipment & Consumables 6.4 9.3 9.0 8.4 Other 1.0 1.3 1.1 1.9 Total $ 13.6 $ 14.8 $ 17.9 $ 18.5 Restructuring related charges were reflected in the following captions in the accompanying Condensed Consolidated Statements of Operations ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Cost of sales $ 4.8 $ 6.9 $ 6.3 $ 6.6 Selling, general and administrative expenses 8.8 7.9 11.6 11.9 Total $ 13.6 $ 14.8 $ 17.9 $ 18.5

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2023
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	The table below presents the computation of basic and diluted earnings per share ($ and shares in millions, except per share amounts): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Numerator: Income from continuing operations, net of tax $ 51.9 $ 44.5 $ 95.7 $ 114.9 Income from discontinued operations, net of tax $ — $ 2.6 $ — $ 7.1 Net income $ 51.9 $ 47.1 $ 95.7 $ 122.0 Denominator: Weighted-average common shares outstanding used in basic earnings per share 164.0 162.9 163.8 162.6 Incremental common shares from: Assumed exercise of dilutive options and vesting of dilutive restricted stock units 2.4 3.3 2.6 3.8 Assumed conversion of the Notes 9.9 12.3 10.5 12.8 Weighted average common shares outstanding used in diluted earnings per share 176.3 178.5 176.9 179.2 Earnings per share: Earnings from continuing operations - basic $ 0.32 $ 0.27 $ 0.58 $ 0.71 Earnings from continuing operations - diluted $ 0.29 $ 0.25 $ 0.54 $ 0.64 Earnings from discontinued operations - basic $ — $ 0.02 $ — $ 0.04 Earnings from discontinued operations - diluted $ — $ 0.01 $ — $ 0.04 Earnings - basic $ 0.32 $ 0.29 $ 0.58 $ 0.75 Earnings - diluted $ 0.29 $ 0.26 $ 0.54 $ 0.68
Schedule of antidilutive securities excluded from computation of earnings per share	The following table presents the number of outstanding securities not included in the computation of diluted income per share, because their effect was anti-dilutive (in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Stock-based awards 2.1 1.9 2.0 1.3

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2023
Segment Reporting [Abstract]
Segment results	Segment related information is shown below ($ in millions): Three Months Ended Six Months Ended June 30, 2023 July 1, 2022 June 30, 2023 July 1, 2022 Sales: Specialty Products & Technologies $ 417.0 $ 407.7 $ 827.0 $ 804.8 Equipment & Consumables 245.4 238.1 462.6 472.4 Total $ 662.4 $ 645.8 $ 1,289.6 $ 1,277.2 Operating profit and reconciliation to income before taxes from continuing operations: Specialty Products & Technologies $ 55.7 $ 74.0 $ 126.8 $ 144.3 Equipment & Consumables 48.4 30.2 80.9 75.7 Other (25.2) (39.0) (56.7) (63.3) Operating profit 78.9 65.2 151.0 156.7 Nonoperating income (expense): Other income 7.1 0.3 7.4 0.6 Interest expense, net (17.4) (6.4) (34.1) (12.3) Income before taxes from continuing operations $ 68.6 $ 59.1 $ 124.3 $ 145.0 Identifiable assets: June 30, 2023 December 31, 2022 Specialty Products & Technologies $ 3,438.2 $ 3,475.7 Equipment & Consumables 2,473.5 2,455.3 Other 695.5 656.0 Total $ 6,607.2 $ 6,587.0

Business And Basis Of Present_2

Business And Basis Of Presentation - Narrative (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($) segment	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Jul. 01, 2022 USD ($)	Apr. 01, 2022 USD ($)	Dec. 31, 2021 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of business segments (in segments) | segment	2
Long-term debt	$ 1,387.1		$ 1,380.7
Increase (decrease) in stockholders' equity	4,311		4,206.9
Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in stockholders' equity	3,719.2	$ 3,712.8	3,699	$ 3,678.4	$ 3,667.9	$ 3,732.6
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in stockholders' equity	$ 827.1	$ 775.2	$ 731.4	$ 610.3	$ 563.2	466.9
Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net deferred tax liability						18.6
Adjustment | Additional Paid-in Capital
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in stockholders' equity						(77.8)
Adjustment | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) in stockholders' equity						21.4
Adjustment | Convertible Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Long-term debt						$ 75

Acquisitions - Narrative (Detai

Acquisitions - Narrative (Details) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended
	Jul. 05, 2022	Apr. 20, 2022	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Contingent consideration				$ 6,000		$ 6,000
Osteogenics Biomedical Inc
Business Acquisition [Line Items]
Consideration transferred	$ 128,200
Weighted-average useful life of acquired intangible assets				10 years
Carestream Dental Technology
Business Acquisition [Line Items]
Consideration transferred		$ 580,300
Contingent consideration		$ 7,500
Weighted-average useful life of acquired intangible assets				8 years
Acquisition costs			$ 8,200		$ 10,700

Acquisitions - Fair Values of A

Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022	Jul. 05, 2022	Apr. 20, 2022
Assets acquired:
Goodwill	$ 3,493.8	$ 3,496.6
Osteogenics Biomedical Inc
Assets acquired:
Cash			$ 2.1
Accounts receivable			2.5
Inventories			13.3
Intangible assets			53
Property, plant and equipment			0
Prepaids and Other Current Assets			1.3
Goodwill			77.3
Non-current deferred tax asset			0
Operating lease right-of-use assets			2.6
Other long-term assets			4.9
Total assets acquired			157
Liabilities assumed:
Accounts payable			(4.1)
Accrued expenses and other liabilities			(2.5)
Non-current deferred tax liability			(14.3)
Other long-term liabilities			(5.8)
Operating lease liabilities			(2.1)
Total liabilities assumed			(28.8)
Total net assets acquired			$ 128.2
Carestream Dental Technology
Assets acquired:
Cash				$ 2.7
Accounts receivable				0.1
Inventories				6.1
Intangible assets				129.8
Property, plant and equipment				0.3
Prepaids and Other Current Assets				0
Goodwill				373.1
Non-current deferred tax asset				96
Operating lease right-of-use assets				0.9
Other long-term assets				0.2
Total assets acquired				609.2
Liabilities assumed:
Accounts payable				(0.5)
Accrued expenses and other liabilities				(27.9)
Non-current deferred tax liability				0
Other long-term liabilities				0
Operating lease liabilities				(0.5)
Total liabilities assumed				(28.9)
Total net assets acquired				$ 580.3

Discontinued Operations - Narra

Discontinued Operations - Narrative (Details) - Discontinued operations disposed of by sale - Plamenca - USD ($) $ in Millions	6 Months Ended
	Jul. 01, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Consideration		$ 386.4
Proceeds from sale of KaVo treatment unit and instrument business, net	$ 30

Discontinued Operations - Sched

Discontinued Operations - Schedule of Discontinued Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Operating expenses:
Income from discontinued operations, net of tax	$ 0	$ 2.6	$ 0	$ 7.1
Discontinued operations disposed of by sale | Plamenca
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sales		2		8.9
Cost of sales		1.1		7
Gross profit		0.9		1.9
Operating expenses:
Selling, general and administrative		1		2.1
Research and development		0		0
Operating loss		(0.1)		(0.2)
Income tax expense		0		0
Loss from discontinued operations		(0.1)		(0.2)
Gain on sale of discontinued operations, net of tax		2.7		7.3
Net income from discontinued operations		$ 2.6		$ 7.1

Credit Losses - Narrative (Deta

Credit Losses - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Credit Loss [Abstract]
Number of portfolio segments (in segments)	1

Credit Losses - Allowance for C

Credit Losses - Allowance for Credit Losses (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 16.2
Foreign currency translation	(0.2)
Provision for credit losses	3.2
Write-offs charged against the allowance	(1.8)
Recoveries	(1.1)
Ending balance	$ 16.3

Inventories - Summary (Details)

Inventories - Summary (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 229.5	$ 229.2
Work in process	22.2	23.9
Raw materials	102.2	103.4
Reserve for inventory obsolescence	(56.9)	(55.7)
Total	$ 297	$ 300.8

Property, Plant And Equipment_2

Property, Plant And Equipment (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 626.8	$ 605.9
Less: accumulated depreciation	(326.7)	(312.3)
Property, plant and equipment, net	300.1	293.6
Land and improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	10	10
Buildings and improvements
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	158.3	154.5
Machinery, equipment and other assets
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	394.7	370.2
Construction in progress
Property, Plant and Equipment [Line Items]
Gross property, plant and equipment	$ 63.8	$ 71.2

Goodwill - Rollforward and Carr

Goodwill - Rollforward and Carrying Value of Goodwill (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 3,496.6
Foreign currency translation	(2.8)
Ending balance	3,493.8
Specialty Products & Technologies
Goodwill [Roll Forward]
Beginning balance	2,047.8
Foreign currency translation	(7.8)
Ending balance	2,040
Equipment & Consumables
Goodwill [Roll Forward]
Beginning balance	1,448.8
Foreign currency translation	5
Ending balance	$ 1,453.8

Accrued Expenses And Other Li_3

Accrued Expenses And Other Liabilities - Summary (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Current
Compensation and benefits	$ 114.1	$ 148
Sales and product allowances	63.7	85.1
Contract liabilities	102.6	78.9
Taxes, income and other	37.8	42.1
Restructuring-related employee severance, benefits and other	11.1	18.9
Pension benefits	5.6	5.6
Loss contingencies	10.3	8.1
Derivative financial instruments	0	0
Other	88.8	84.7
Total	434	471.4
Noncurrent
Compensation and benefits	21.1	17.5
Sales and product allowances	1.5	1.3
Contract liabilities	8.3	8.6
Taxes, income and other	65.8	68.6
Restructuring-related employee severance, benefits and other	0	0
Pension benefits	16.6	17.5
Loss contingencies	26.7	27.6
Derivative financial instruments	1.7	0
Other	11.3	10.2
Total	$ 153	$ 151.3

Hedging Transactions And Deri_3

Hedging Transactions And Derivative Financial Instruments - Narrative (Details)		3 Months Ended		6 Months Ended
	Jan. 17, 2023 USD ($)	Jun. 30, 2023 USD ($)	Jul. 01, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jul. 01, 2022 USD ($)	Jun. 30, 2023 EUR (€)	Dec. 31, 2022 USD ($)	Sep. 20, 2019 USD ($)	Sep. 20, 2019 EUR (€)
Derivative [Line Items]
Derivative notional amount		$ 377,000,000	$ 1,116,600,000	$ 377,000,000	$ 1,116,600,000
Total debt		1,387,100,000		1,387,100,000			$ 1,380,700,000
Amounts reclassified from accumulated other comprehensive loss, net of income taxes		0	0	0	0
Amount reclassified from AOCI into income		0	$ 0	0	$ 0
Cross-currency swap derivative contracts
Derivative [Line Items]
Derivative, term	2 years
Derivative notional amount	$ 150,000,000
US term loan due 2024
Derivative [Line Items]
Total debt		648,800,000		648,800,000			648,300,000	$ 650,000,000
Term loan								$ 650,000,000
Euro term loan due 2024
Derivative [Line Items]
Total debt		$ 226,800,000		$ 226,800,000			$ 222,400,000
Term loan | €						€ 208,000,000			€ 208,000,000

Hedging Transactions And Deri_4

Hedging Transactions And Derivative Financial Instruments - Summary of Notional Values and Pretax Impact in Fair Values of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	$ 377	$ 1,116.6	$ 377	$ 1,116.6
Gain (loss) recognized in OCI	(3.2)	50	(6)	76.5
Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	0		0
Net investment hedging | Foreign currency denominated debt
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	227	216.6	227	216.6
Gain (loss) recognized in OCI	(1.5)	13.1	(4.3)	19.9
Net investment hedging | Foreign currency contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	150	650	150	650
Gain (loss) recognized in OCI	(1.7)	36.2	(1.7)	54.1
Net investment hedging | Interest rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Notional Amount	0	250	0	250
Gain (loss) recognized in OCI	$ 0	$ 0.7	$ 0	$ 2.5

Hedging Transactions And Deri_5

Hedging Transactions And Derivative Financial Instruments - Derivative and Nonderivative Debt Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Derivatives, Fair Value [Line Items]
Other long-term liabilities	$ 1.7	$ 0
Derivative Liability, Statement of Financial Position [Extensible Enumeration]	Other long-term liabilities
Long-term debt
Derivatives, Fair Value [Line Items]
Long-term debt	$ 227	$ 222.7

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Liabilities:
Cross-currency swap derivative contracts	$ 1.7	$ 0
Deferred compensation plans	19.4	15.8
Contingent consideration	6	6
Quoted Prices in Active Market (Level 1)
Liabilities:
Deferred compensation plans	0	0
Contingent consideration	0	0
Significant Other Observable Inputs (Level 2)
Liabilities:
Deferred compensation plans	19.4	15.8
Contingent consideration	0	0
Significant Unobservable Inputs (Level 3)
Liabilities:
Deferred compensation plans	0	0
Contingent consideration	6	$ 6
Cross-currency swap derivative contracts
Liabilities:
Cross-currency swap derivative contracts	1.7
Cross-currency swap derivative contracts | Quoted Prices in Active Market (Level 1)
Liabilities:
Cross-currency swap derivative contracts	0
Cross-currency swap derivative contracts | Significant Other Observable Inputs (Level 2)
Liabilities:
Cross-currency swap derivative contracts	1.7
Cross-currency swap derivative contracts | Significant Unobservable Inputs (Level 3)
Liabilities:
Cross-currency swap derivative contracts	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 6	$ 6
Cross-currency swap derivative contracts	1.7	0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	6	6
Convertible senior notes due 2025	511.5	510
Long-term debt	875.6	870.7
Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	6	6
Convertible senior notes due 2025	868.4	873
Long-term debt	875.6	870.7
Cross-currency swap derivative contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cross-currency swap derivative contracts	1.7
Cross-currency swap derivative contracts | Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cross-currency swap derivative contracts	1.7	0
Cross-currency swap derivative contracts | Fair Value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cross-currency swap derivative contracts	$ 1.7	$ 0

Warranty - Narrative (Details)

Warranty - Narrative (Details)	6 Months Ended
	Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
Product warranty period	90 days

Warranty - Warranty Accrual (De

Warranty - Warranty Accrual (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Beginning balance	$ 9.2
Accruals for warranties issued during the year	6.7
Settlements made	(6.5)
Effect of foreign currency translation	0.1
Ending balance	$ 9.5

Litigation And Contingencies -

Litigation And Contingencies - Narrative (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Accrual for legal matters	$ 37	$ 35.7

Debt And Credit Facilities - Co

Debt And Credit Facilities - Components Of Debt (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022	Sep. 20, 2019
Debt Instrument [Line Items]
Total debt	$ 1,387.1	$ 1,380.7
Less: current portion	(511.5)	(510)
Long-term debt	875.6	870.7
US term loan due 2024
Debt Instrument [Line Items]
Total debt	648.8	648.3	$ 650
Euro term loan due 2024
Debt Instrument [Line Items]
Total debt	226.8	222.4
Convertible Debt | Convertible Senior Notes
Debt Instrument [Line Items]
Total debt	$ 511.5	$ 510

Debt And Credit Facilities - Na

Debt And Credit Facilities - Narrative (Details) $ / shares in Units, shares in Millions		6 Months Ended	12 Months Ended
	May 21, 2020 USD ($) tradingDay $ / shares shares	Jun. 30, 2023 USD ($) tradingDay $ / shares	Dec. 31, 2022 USD ($) tradingDay $ / shares	Jun. 30, 2023 EUR (€)	Jul. 01, 2022	Sep. 20, 2019 USD ($)	Sep. 20, 2019 EUR (€)
Debt Instrument [Line Items]
Long-term debt		$ 1,387,100,000	$ 1,380,700,000
Rate in excess of Federal funds rate		0.0050		0.0050
Rate in excess of Eurocurrency rate		0.010		0.010
Leverage ratio		3.75		3.75
Contingency provision on the ratio of indebtedness to net capital		4.25		4.25
Contingency provision, purchase price in excess of $100 million		$ 100,000,000
Interest coverage ratio (at least)		3		3
Conversion price (in USD per share) | $ / shares		$ 21.01	$ 21.01
Conversion ratio		0.0475862
US term loan due 2024
Debt Instrument [Line Items]
Long-term debt		$ 648,800,000	$ 648,300,000			$ 650,000,000
Term loan						$ 650,000,000
Loan facility interest rates		6.44%	5.98%
Euro term loan due 2024
Debt Instrument [Line Items]
Long-term debt		$ 226,800,000	$ 222,400,000
Term loan | €				€ 208,000,000			€ 208,000,000
Loan facility interest rates		4.49%	3.28%
Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity		$ 750,000,000
Increase limit of revolving credit facility		350,000,000
Line of credit facility, outstanding borrowings		0	$ 0
Revolving Credit Facility | Standby letters of credit
Debt Instrument [Line Items]
Revolving credit facility maximum borrowing capacity		$ 20,000,000
Minimum
Debt Instrument [Line Items]
Facility fee		0.09%
Maximum
Debt Instrument [Line Items]
Facility fee		0.225%
LIBOR | Minimum | Credit facility
Debt Instrument [Line Items]
Margin spread of variable interest rate		0.785%
LIBOR | Maximum | Credit facility
Debt Instrument [Line Items]
Margin spread of variable interest rate		1.625%
Base Rate | Minimum
Debt Instrument [Line Items]
Margin spread of variable interest rate		0%
Base Rate | Maximum
Debt Instrument [Line Items]
Margin spread of variable interest rate		0.625%
Convertible Debt | 2.375% convertible senior notes over allotment option
Debt Instrument [Line Items]
Term loan	$ 67,500,000
Convertible Debt | 2.375% convertible senior notes
Debt Instrument [Line Items]
Long-term debt		$ 511,500,000	$ 510,000,000
Term loan	517,500,000
Proceeds from issuance of convertible senior notes	$ 502,600,000
Interest rate	2.375%
Conversion price (in USD per share) | $ / shares	$ 21.01
Redemption price	100%
Threshold percentage of stock price trigger	130%	130%	130%
Convertible debt, trading days (in trading days) | tradingDay	20	20	20
Convertible debt, consecutive trading days (in trading days) | tradingDay	30	30	30
Effective interest rate		3%		3%	3%
If-converted value in excess of principal		$ 315,800,000	$ 311,700,000
Convertible Debt | 2.375% convertible senior notes, capped calls
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares	$ 23.79
Convertible debt, stock price trigger (in USD per share) | $ / shares	$ 21.01
Convertible debt, capped calls (in shares) | shares	2.9
Convertible debt expense, capped calls	$ 20,700,000

Debt And Credit Facilities - In

Debt And Credit Facilities - Interest Expense (Details) - Convertible Debt - 2.375% convertible senior notes - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Debt Instrument [Line Items]
Contractual interest expense	$ 3	$ 3	$ 6.1	$ 6.1
Amortization of debt issuance costs	0.8	0.8	1.5	1.5
Total interest expense	$ 3.8	$ 3.8	$ 7.6	$ 7.6

Debt And Credit Facilities - Un

Debt And Credit Facilities - Unamortized Debt Issuance Costs (Details) - USD ($) $ in Millions	Jun. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Debt issuance costs	$ 7.4	$ 9.5
Convertible Senior Notes | Convertible Debt
Debt Instrument [Line Items]
Debt issuance costs	6	7.5
Term Loan
Debt Instrument [Line Items]
Debt issuance costs	1.2	1.7
Euro Term Loan
Debt Instrument [Line Items]
Debt issuance costs	$ 0.2	$ 0.3

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss - Rollforward (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Jun. 30, 2023	Mar. 31, 2023	Jul. 01, 2022	Apr. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period		$ 4,206.9			$ 4,206.9
Total other comprehensive loss, net of income taxes	$ (26.3)		$ (72.5)		(11.8)	$ (130.8)
Balance, end of period	4,311				4,311
Accumulated Other Comprehensive Loss
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(210.6)	(225.1)	(201.8)	$ (143.5)	(225.1)	(143.5)
Decrease	(26.7)		(59.7)		(12.6)	(111.7)
Income tax impact	0.8		(12.7)		1.5	(18.9)
Other comprehensive (loss) income before reclassifications, net of income taxes	(25.9)		(72.4)		(11.1)	(130.6)
Increase	(0.5)		0		(0.9)	(0.2)
Income tax impact	0.1		(0.1)		0.2	0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	(0.4)		(0.1)		(0.7)	(0.2)
Total other comprehensive loss, net of income taxes	(26.3)	14.5	(72.5)	(58.3)	(11.8)	(130.8)
Balance, end of period	(236.9)	(210.6)	(274.3)	(201.8)	(236.9)	(274.3)
Foreign Currency Translation Adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	(225.7)	(240.5)	(199.2)	(139.6)	(240.5)	(139.6)
Decrease	(26.7)		(60.4)		(12.6)	(114.2)
Income tax impact	0.8		(12.5)		1.5	(18.3)
Other comprehensive (loss) income before reclassifications, net of income taxes	(25.9)		(72.9)		(11.1)	(132.5)
Increase	0		0		0	0
Income tax impact	0		0		0	0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	0		0		0	0
Total other comprehensive loss, net of income taxes	(25.9)		(72.9)		(11.1)	(132.5)
Balance, end of period	(251.6)	(225.7)	(272.1)	(199.2)	(251.6)	(272.1)
Unrealized Gain (Loss) on Cash Flow Hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period			(0.3)	(1.7)		(1.7)
Decrease			0.7			2.5
Income tax impact			(0.2)			(0.6)
Other comprehensive (loss) income before reclassifications, net of income taxes			0.5			1.9
Increase			0			0
Income tax impact			0			0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes			0			0
Total other comprehensive loss, net of income taxes			0.5			1.9
Balance, end of period			0.2	(0.3)		0.2
Unrealized Pension Costs
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance, beginning of period	15.1	15.4	(2.3)	(2.2)	15.4	(2.2)
Decrease	0		0		0	0
Income tax impact	0		0		0	0
Other comprehensive (loss) income before reclassifications, net of income taxes	0		0		0	0
Increase	(0.5)		0		(0.9)	(0.2)
Income tax impact	0.1		(0.1)		0.2	0
Amounts reclassified from accumulated other comprehensive loss, net of income taxes	(0.4)		(0.1)		(0.7)	(0.2)
Total other comprehensive loss, net of income taxes	(0.4)		(0.1)		(0.7)	(0.2)
Balance, end of period	$ 14.7	$ 15.1	$ (2.4)	$ (2.3)	$ 14.7	$ (2.4)

Revenue - Disaggregation by Rev

Revenue - Disaggregation by Revenue Type and Geographical Region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Disaggregation of Revenue [Line Items]
Sales	$ 662.4	$ 645.8	$ 1,289.6	$ 1,277.2
North America
Disaggregation of Revenue [Line Items]
Sales	340.4	339.8	665.1	675.4
Western Europe
Disaggregation of Revenue [Line Items]
Sales	144.9	129.9	294	268.2
Other developed markets
Disaggregation of Revenue [Line Items]
Sales	32.3	33.3	64.9	68
Emerging markets
Disaggregation of Revenue [Line Items]
Sales	144.8	142.8	265.6	265.6
Specialty Products & Technologies
Disaggregation of Revenue [Line Items]
Sales	417	407.7	827	804.8
Specialty Products & Technologies | North America
Disaggregation of Revenue [Line Items]
Sales	178.3	179.5	363.6	358.8
Specialty Products & Technologies | Western Europe
Disaggregation of Revenue [Line Items]
Sales	114.6	100.5	231.6	206.8
Specialty Products & Technologies | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	22.2	23	46.2	47.4
Specialty Products & Technologies | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	101.9	104.7	185.6	191.8
Equipment & Consumables
Disaggregation of Revenue [Line Items]
Sales	245.4	238.1	462.6	472.4
Equipment & Consumables | North America
Disaggregation of Revenue [Line Items]
Sales	162.1	160.3	301.5	316.6
Equipment & Consumables | Western Europe
Disaggregation of Revenue [Line Items]
Sales	30.3	29.4	62.4	61.4
Equipment & Consumables | Other developed markets
Disaggregation of Revenue [Line Items]
Sales	10.1	10.3	18.7	20.6
Equipment & Consumables | Emerging markets
Disaggregation of Revenue [Line Items]
Sales	$ 42.9	$ 38.1	$ 80	$ 73.8

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details) $ in Millions	Jun. 30, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation	$ 73.1
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Expected timing of satisfaction	12 months

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Contract liability	$ 110.9		$ 110.9		$ 87.5
Revenue recognized			$ 53.2	$ 36.1
Revenue Benchmark | Customer Concentration Risk | Largest customer
Disaggregation of Revenue [Line Items]
Concentration risk percentage	12%	12%	11%	11%

Restructuring Activities And _3

Restructuring Activities And Related Impairments - Schedule Of Restructuring And Related Costs (Details) $ in Millions	6 Months Ended
	Jun. 30, 2023 USD ($)
Restructuring Reserve [Roll Forward]
Balance at beginning of year	$ 18.9
Costs incurred	17.5
Paid	(25.3)
Balance at end of year	11.1
Employee Severance and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	18.2
Costs incurred	13.2
Paid	(21.2)
Balance at end of year	10.2
Facility Exit and Related
Restructuring Reserve [Roll Forward]
Balance at beginning of year	0.7
Costs incurred	4.3
Paid	(4.1)
Balance at end of year	$ 0.9

Restructuring Activities And _4

Restructuring Activities And Related Impairments - Schedule Of Restructuring And Other Related Charges By Segment (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 13.6	$ 14.8	$ 17.9	$ 18.5
Specialty Products & Technologies
Restructuring Cost and Reserve [Line Items]
Costs incurred	6.2	4.2	7.8	8.2
Equipment & Consumables
Restructuring Cost and Reserve [Line Items]
Costs incurred	6.4	9.3	9	8.4
Other
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 1	$ 1.3	$ 1.1	$ 1.9

Restructuring Activities And _5

Restructuring Activities And Related Impairments - Schedule Of Restructuring Reserve By Type Of Cost (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 13.6	$ 14.8	$ 17.9	$ 18.5
Cost of sales
Restructuring Cost and Reserve [Line Items]
Costs incurred	4.8	6.9	6.3	6.6
Selling, general and administrative expenses
Restructuring Cost and Reserve [Line Items]
Costs incurred	$ 8.8	$ 7.9	$ 11.6	$ 11.9

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	24.30%	24.70%	23%	20.80%

Earnings Per Share - Narrative

Earnings Per Share - Narrative (Details) - $ / shares	Jun. 30, 2023	Dec. 31, 2022	May 21, 2020
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Conversion price (in USD per share)	$ 21.01	$ 21.01
2.375% convertible senior notes | Convertible Debt
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]
Conversion price (in USD per share)			$ 21.01
Dilution threshold (in USD per share)	$ 23.79

Earnings Per Share - Components

Earnings Per Share - Components of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Numerator:
Income from continuing operations, net of tax	$ 51.9	$ 44.5	$ 95.7	$ 114.9
Income from discontinued operations, net of tax	0	2.6	0	7.1
Net income	$ 51.9	$ 47.1	$ 95.7	$ 122
Denominator:
Weighted-average common shares outstanding used in basic earnings per share (in shares)	164	162.9	163.8	162.6
Assumed exercise of dilutive options and vesting of dilutive restricted stock units (in shares)	2.4	3.3	2.6	3.8
Assumed conversion of the Notes (in shares)	9.9	12.3	10.5	12.8
Weighted average common shares outstanding used in diluted earnings (loss) per share (in shares)	176.3	178.5	176.9	179.2
Earnings per share:
Earnings from continuing operations - basic (in USD per share)	$ 0.32	$ 0.27	$ 0.58	$ 0.71
Earnings from continuing operations - diluted (in USD per share)	0.29	0.25	0.54	0.64
Earnings (loss) from discontinued operations - basic (in USD per share)	0	0.02	0	0.04
Earnings (loss) from discontinued operations - diluted (in USD per share)	0	0.01	0	0.04
Earnings - basic (in USD per share)	0.32	0.29	0.58	0.75
Earnings - diluted (in USD per share)	$ 0.29	$ 0.26	$ 0.54	$ 0.68

Earnings Per Share - Securities

Earnings Per Share - Securities Not Included in the Computation of Diluted Loss Income per Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022
Stock-based awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of diluted (loss) income per share (in shares)	2.1	1.9	2	1.3

Segment Information - Narrative

Segment Information - Narrative (Details)	6 Months Ended
	Jun. 30, 2023 segment
Segment Reporting [Abstract]
Number of reportable segments (in segments)	2
Number of operating segments (in segments)	2

Segment Information - Segment R

Segment Information - Segment Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jul. 01, 2022	Jun. 30, 2023	Jul. 01, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 662.4	$ 645.8	$ 1,289.6	$ 1,277.2
Operating profit (loss)	78.9	65.2	151	156.7
Other income	7.1	0.3	7.4	0.6
Interest expense, net	(17.4)	(6.4)	(34.1)	(12.3)
Income before income taxes	68.6	59.1	124.3	145
Identifiable assets	6,607.2		6,607.2		$ 6,587
Other
Segment Reporting Information [Line Items]
Operating profit (loss)	(25.2)	(39)	(56.7)	(63.3)
Identifiable assets	695.5		695.5		656
Specialty Products & Technologies
Segment Reporting Information [Line Items]
Sales	417	407.7	827	804.8
Specialty Products & Technologies | Operating segments
Segment Reporting Information [Line Items]
Sales	417	407.7	827	804.8
Operating profit (loss)	55.7	74	126.8	144.3
Identifiable assets	3,438.2		3,438.2		3,475.7
Equipment & Consumables
Segment Reporting Information [Line Items]
Sales	245.4	238.1	462.6	472.4
Equipment & Consumables | Operating segments
Segment Reporting Information [Line Items]
Sales	245.4	238.1	462.6	472.4
Operating profit (loss)	48.4	$ 30.2	80.9	$ 75.7
Identifiable assets	$ 2,473.5		$ 2,473.5		$ 2,455.3

Uncategorized Items - nvst-2023

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2020-06 [Member]